Private biotech company focused on developing modulators of intracellular protein-protein interactions employing a proprietary technology platform. The most advanced of these first-in-class therapeutics, an oral modulator of dysregulated transcription, is currently in preclinical development.
- http://intherabio.com/
- +41 43 477 94 66
